New Roche Acquisition Kapa Will Continue to Support Other NGS Platforms, Power New NGS Apps

NEW YORK (GenomeWeb) – Following its acquisition of Kapa Biosystems, Roche will continue to offer Kapa's current product portfolio, including library reagent kits for next-generation sequencing, while developing new products for NGS using Kapa's protein engineering technology.

Roche said last week that it plans to acquire Kapa Biosystems for an undisclosed amount. The company, headquartered in Wilmington, Massachusetts, offers a variety of reagent kits for NGS, PCR, and qPCR applications, among them library preparation, quantification, and amplification kits for NGS. Its products support both Illumina's and Thermo Fisher Scientific's Ion Torrent sequencing platforms, which have outdriven Roche's own 454 platform in recent years.

Customers can expect current products to remain available after the acquisition closes. According to Dan Zabrowski, head of Roche's Sequencing Unit, Kapa will "continue to sell as they do today" and "will honor existing agreements," such as Kapa's recent contract with 10X Genomics to supply DNA library prep reagents for that firm's GemCode platform.

In addition, Roche will use Kapa's proprietary directed evolution protein engineering technology to "tailor enzymes to suit specific applications in next-generation DNA and RNA sequencing, DNA amplification, and molecular diagnostics," Zabrowski told GenomeWeb via email.

"NGS library preparation is enzyme intensive and therefore the Kapa technology provides a collection of essential components to our fully integrated NGS solution development [and enables] Roche to improve the workflow of all NGS platforms," he said. "Kapa enzymes have the potential to improve the performance of the entire sequencing workflow and complement our existing technologies and expertise."

Operationally, it appears as though Kapa will largely remain unchanged. Kapa "is a strong company with excellent management," Zabrowski said, and Roche will maintain the firm's current operations in Wilmington and Cape Town, South Africa, while integrating it "as it makes sense to leverage our current Roche expertise and infrastructure."

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Sponsored by
Sophia Genetics

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Sponsored by

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.